Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, , Seoul, Republic of Korea.
J Clin Pathol. 2014 Mar;67(3):216-21. doi: 10.1136/jclinpath-2013-201883. Epub 2013 Sep 23.
Due to the rarity of small intestine adenocarcinoma (SIAC), estimating the prognosis for patients with surgically resected SIAC is difficult. Overexpression of S100A4 has been linked to worse patient survival in several malignant neoplasms, but its significance in SIAC has not been determined.
S100A4 protein expression was assessed in 197 surgically resected SIAC cases and compared with clinicopathological factors, including patient survival.
A progressive increase in S100A4 labelling was observed in normal intestinal epithelium, adenoma and adenocarcinoma (p<0.001), and 50 SIAC cases (26.2%) showed strong S100A4 expression. Patients with SIAC with strong S100A4 expression had a higher pT classification (p=0.05), as well as increased lymph node metastasis (p=0.009) and perineural invasion (p=0.002). Patients with SIAC with strong S100A4 expression had significantly worse survival (median survival, 21 months) than those with weak/no S100A4 expression (42.5 months) by univariable (p=0.04) and multivariable (p=0.01) analyses.
S100A4 overexpression is observed in a subset of SIACs, is associated with advanced disease and can be used as a prognostic indicator of poor prognosis in patients with SIAC.
由于小肠腺癌(SIAC)较为罕见,因此评估接受手术切除的 SIAC 患者的预后较为困难。S100A4 的过表达与多种恶性肿瘤患者的生存率降低有关,但它在 SIAC 中的意义尚未确定。
评估了 197 例接受手术切除的 SIAC 病例中 S100A4 蛋白的表达情况,并将其与包括患者生存在内的临床病理因素进行了比较。
在正常肠上皮、腺瘤和腺癌中观察到 S100A4 标记的逐渐增加(p<0.001),并且 50 例 SIAC 病例(26.2%)表现出强烈的 S100A4 表达。S100A4 表达较强的 SIAC 患者具有更高的 pT 分级(p=0.05)、淋巴结转移增加(p=0.009)和神经周围侵犯(p=0.002)。S100A4 表达较强的 SIAC 患者的生存时间明显短于 S100A4 表达较弱/无的患者(中位生存时间:21 个月 vs. 42.5 个月),这在单变量(p=0.04)和多变量(p=0.01)分析中均得到证实。
S100A4 的过表达在一部分 SIAC 中观察到,与晚期疾病相关,可作为 SIAC 患者预后不良的预后指标。